Drug Development
Drug Development
Nanoparticles: Recovery of Drug Delivery Nanoparticles from Human Plasma Using an Electrokinetic Platform Technology
Ibsen S, Sonnenberg A, Schutt C, Mukthavaram R, Yeh Y, Ortac I, Manouchehri S, Kesari S, Esener S, Heller MJ. Small. 2015 Oct;11(38):4990.
Drug Development
Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction
Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, Cho YJ, Pingle SC, Crawford JR, Piccioni DE, Kesari S. Oncotarget. 2015 Jan 20;6(2):1157-70.
Drug Development
In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, Kapoor S, Shetty K, Aggrawal A, Vali S, Abbasi T, Chien S, Kesari S. Br J Cancer. 2014 Oct 14;111(8):1562-71.
Drug Development
Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes
Mukthavaram R, Shi G, Kesari S, Simberg D. J Control Release. 2014 Jun 10;183:146-53.
Drug Development
PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression
Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT. J Neurooncol. 2014 Jan;116(1):89-97.
Drug Development
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S. J Transl Med. 2014 Jan 17;12:13.